^
    Back
    Association details:
    Biomarker:TP53 deletion
    Cancer:Diffuse Large B Cell Lymphoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SOHO 2023
    Title:

    17P (TP53) Deletion Determines Worse Survival in Diffuse Large B‑Cell Lymphoma Patients After First‑Line Treatment With Immunochemotherapy:A Retrospective Study of 151 Patients

    Published date:
    09/01/2023
    Excerpt:
    CONTRADICTING EVIDENCE: Del(17p) was independently and statistically significantly associated with worse overall survival (53% vs 76%, P<0.05), as well as IPI>2 (52% vs 82%, P<0.05)….Del(17p) was an independent predictor of survival in patients with DLBCL treated with first-line immunochemotherapy.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMESFOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROMA CONSECUTIVE COHORT IN CHINA

    Published date:
    05/11/2023
    Excerpt:
    However, DH/TH and 17p/TP53 deletion were still associated with a poorer OS in the HR group ( P =0.004 and 0.014)….This is the first and largest single-center study in China to report the treatment of young DLBCL patients with risk- adapted therapy, in which IIC was applied to selected patients with clinically or biologically high-risk features and showed favorable results.
    Secondary therapy:
    Chemotherapy